EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

Autor: Ardito, Christine M., Grüner, Barbara M., Takeuchi, Kenneth K., Lubeseder-Martellato, Clara, Teichmann, Nicole, Mazur, Pawel K., DelGiorno, Kathleen E., Carpenter, Eileen S., Halbrook, Christopher J., Hall, Jason C., Pal, Debjani, Briel, Thomas, Herner, Alexander, Trajkovic-Arsic, Marija, Sipos, Bence, Liou, Geou-Yarh, Storz, Peter, Murray, Nicole R., Threadgill, David W., Sibilia, Maria, Washington, M. Kay, Wilson, Carole L., Schmid, Roland M., Raines, Elaine W., Crawford, Howard C., Siveke, Jens T.

Publikováno v: In Cancer Cell 11 September 2012 22(3):304-317

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Role of EGFR / KRAS Downstream Targets MEK, EGR1 and KLF5 in Pancreatic Cancer Initiation and Progression

Autor: Briel, Thomas

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumours known and incurable to this day. This work was focussed on the MEK - ERK pathway, essential for PDAC initiation, using genetically engineered mouse models. Sustained MEK si

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______518::7989772f4a329e6857a4bc77730d8fd6
https://mediatum.ub.tum.de/1220374

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.

Autor: Stoffel ST; Institute of Pharmaceutical Medicine, University of Basel, Switzerland / Swiss Group for Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland., von Moos R; Department of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland., Thürlimann B; Kantonsspital St. Gallen, Switzerland., Cathomas R; Kantonsspital Graubünden | Department of Hematology/Oncology, Kantonsspital Graubünden., Gillessen S; Department of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland., Zürrer-Härdi U; Kantonsspital Winterthur, Switzerland., von Briel T; Klinik Hirslanden, Zurich, Switzerland., Anchisi S; Hôpital du Valais, Sion, Switzerland., Feller A; Foundation National Institute for Cancer Epidemiology and Registration (NICER), c/o University of Zurich, Switzerland / National Agency for Cancer Registration (NACR) operated by NICER, c/o University of Zurich, Switzerland., Schär C; Swiss Group for Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland., Dietrich D; Swiss Group for Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland., Schwenkglenks M; Institute of Pharmaceutical Medicine, University of Basel, Switzerland., Lupatsch JE; Institute of Pharmaceutical Medicine, University of Basel, Switzerland / Swiss Group for Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland., Mark MT; Department of Haematology/Oncology, Kantonsspital Graubünden, Chur, Switzerland.

Publikováno v: Swiss medical weekly [Swiss Med Wkly] 2021 Mar 01; Vol. 151, pp. w20464. Date of Electronic Publication: 2021 Mar 01 (Print Publication: 2021).